Philippines vs Saudi Arabia: Share of S. aureus infections resistant to methicillin
Philippines
44.4%
in 2022
Saudi Arabia
52.0%
in 2022
Philippines rank
13th
Saudi Arabia rank
11th
Share of S. aureus infections resistant to methicillin over time
- Philippines
- Saudi Arabia
How they compare
Saudi Arabia currently reports 52.0% against 44.4% in Philippines, a difference of 7.6%.
That makes Saudi Arabia's figure about 1.2 times Philippines's.
The two have swapped places 1 time across 6 shared years of data; in 2017 it was Philippines ahead.
Philippines ranks 13th and Saudi Arabia ranks 11th of 45 countries.
Across the 2 decades both report, Philippines averaged higher in 1 and Saudi Arabia in 1.
Head to head by decade
| Decade | Philippines | Saudi Arabia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 54.8% | 42.8% | 11.9% | Philippines |
| 2020s | 44.9% | 67.5% | 22.6% | Saudi Arabia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of s. aureus infections resistant to methicillin, Philippines or Saudi Arabia?
- Saudi Arabia, at 52.0% against 44.4% in Philippines as of 2022.
- What is the difference in share of s. aureus infections resistant to methicillin between Philippines and Saudi Arabia?
- 7.6%, with Saudi Arabia ahead.
- How many years of comparable data are there for Philippines and Saudi Arabia?
- 6 years are reported by both, from 2017 to 2022.
- How do Philippines and Saudi Arabia rank globally for share of s. aureus infections resistant to methicillin?
- Philippines ranks 13th and Saudi Arabia ranks 11th of 45 countries.
- Where does this data come from?
- World Health Organization – processed by Our World in Data, published as Share of S. aureus infections resistant to methicillin. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested (%).